Oncothyreon (ONTY) Misses Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Oncothyreon Reports Full Year and Fourth Quarter 2014 Financial Results
March 10, 2015 4:01 PM EDTSEATTLE, March 10, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq: ONTY) today reported financial results for the year and quarter ended December 31, 2014.
Net loss for the year ended December 31, 2014 was $50.0 million, or $0.64 per basic and diluted share, compared with a net loss of $38.8 million, or $0.62 per basic and diluted share, for the comparable period in 2013. The increase in net loss was due to higher research and development expenses, primarily as a result of an increase of $10.0 million in license fees paid to Array. The increase in net loss was also the result of higher general and... More
Oncothyreon Reports Full Year and Fourth Quarter 2014 Financial Results
March 10, 2015 4:01 PM EDTSEATTLE, March 10, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq: ONTY) today reported financial results for the year and quarter ended December 31, 2014.
Net loss for the year ended December 31, 2014 was $50.0 million, or $0.64 per basic and diluted share, compared with a net loss of $38.8 million, or $0.62 per basic and diluted share, for the comparable period in 2013. The increase in net loss was due to higher research and development expenses, primarily as a result of an increase of $10.0 million in license fees paid to Array. The increase in net loss was also the result of higher general and... More
